Recent News
June 3, 2026 — Waters announced FDA 510(k) clearance of the BD BACTEC FXI Culture System, expanding access to bloodstream infection diagnostics in U.S. laboratories. June 3, 2026 — Company presented at the Jefferies Global Healthcare Conference. June 8, 2026 — Waters launched new reversed-phase bioseparation columns targeting faster GLP‑1 and lipid nanoparticle analyses. June 9, 2026 — Waters introduced a coin-cell differential scanning calorimeter aimed at battery-safety testing. August 26, 2026 — Company scheduled a presentation at the Wells Fargo Healthcare Conference.
Technical Analysis
ADX 24.62 indicates an emerging directional environment rather than a strong trend; this moderating strength suggests recent directional moves carry limited conviction relative to a sustained trend.
DI+ at 25.08 (dip & reversal) registers as bullish, while DI− at 14.80 (dip & reversal) registers as bearish; the simultaneous upward motion in both directional indices implies competing pressure between buyers and sellers rather than a decisive directional advantage.
MACD at 7.92 with a signal line at 8.80 and a MACD trend described as peak & reversal signals bearish momentum; MACD sits below its signal line, consistent with weakening upside momentum.
MRO at 26.67 (positive) indicates the market price sits above the modeled target and carries pressure toward a decrease; the MRO trend showing a dip & reversal reinforces potential downside pressure from an overshoot relative to target levels.
RSI 58.01 with a peak & reversal character points to waning bullish momentum after a recent strength phase rather than fresh overbought extremes; this aligns with other momentum measures that favor near-term pullback risk.
Price sits at $405.84, below the 20‑day average $411.65 and the 12‑day EMA $410.48 (both with peak & reversal notes), yet above the 50‑day average $387.94 and 200‑day average $360.15; this posture supports a short-term consolidation toward near-term support rather than a trend reversal below longer-term averages.
Bollinger bands place the 1x lower band at $405.73, leaving the current price essentially at the lower 1x band and well inside the 2x band range; proximity to the lower band suggests limited immediate downside room before mean reversion pressures could appear, but momentum indicators favor a pullback before any meaningful re-acceleration.
Ichimoku levels put the Kijun‑sen at $396.94 with Senkou A at $364.37 and Senkou B at $342.10; the most relevant near-term support cluster aligns around $397–$394 (Kijun‑sen and the superTrend lower at $394.32), which serves as a logical consolidation floor if momentum-driven weakness unfolds.
Fundamental Analysis
Reported EPS of $3.05 versus an estimate of $3.01 produced an EPS surprise of +1.33%, demonstrating modest beat on the quarter. Forward EPS stands at $4.14, implying earnings power that sits ahead of trailing results but must be viewed against valuation multiples.
Trailing PE equals 118.80, above the industry peer mean of 87.17 and the industry peer median of 78.95; forward PE equals 84.00, slightly above the industry peer mean of 80.78. WMDST’s valuation marks the stock as over‑valued, reflecting these elevated multiples relative to peer averages.
PEG ratio equals 9.16, above the industry peer mean of 8.94 and the industry peer median of 8.26; forward PEG equals 6.48, also above the peer mean. PEG QoQ moved by -411.05% and PEG YoY rose by 155.12% per the supplied figures; these changes underscore dispersion between current multiples and growth expectations.
Earnings growth registers at +12.96% year‑over‑period while earnings growth QoQ shows -132.09% and earnings growth YoY indicates -58.33% based on the provided figures; the year‑over‑period outperformance versus the industry peer mean earnings growth of 10.86% gives some fundamental support, but quarterly dynamics show volatility.
Revenue growth reads 0.0% with QoQ and YoY entries at -100.0% as supplied; cash flow margin and cash flow to earnings report as $0.00 in the provided figures. Invested capital totals $5,108,000,000 and cost of debt equals 1.109%.
Valuation summary: earnings show a small positive surprise and above‑peer earnings growth on the supplied mean, but elevated trailing and forward multiples alongside high PEG values lead WMDST to value the stock as over‑valued. Forward PE compression year‑over‑year (-22.67% per provided forward PE YoY) partially offsets stretched trailing multiples but not enough to change the over‑valuation assessment.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2026-06-30 |
| REPORT DATE: | 2026-08-04 |
| NEXT REPORT DATE: | 2026-11-03 |
| CASH FLOW | Begin Period Cash Flow | — |
| Operating Cash Flow | — | |
| Capital Expenditures | — | |
| Change In Working Capital | — | |
| Dividends Paid | — | |
| Cash Flow Delta | — | |
| End Period Cash Flow | — | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | — | |
| Depreciation and Amortization | — | |
| Research and Development | — | |
| Total Operating Expenses | — | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | — | |
| EBIT | — | |
| Operating Income | — | |
| Interest Income | — | |
| Interest Expense | — | |
| Net Interest Income | — | |
| Income Before Tax | — | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | — | |
| Net Income From Continuing Operations | — | |
| EARNINGS | ||
| EPS Estimate | $ 3.01 | |
| EPS Actual | $ 3.05 | |
| EPS Difference | $ 0.04 | |
| EPS Surprise | 1.329 % | |
| Forward EPS | $ 4.14 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | — | |
| Intangible Assets | — | |
| Net Tangible Assets | — | |
| Total Current Assets | — | |
| Cash and Short-Term Investments | — | |
| Cash | — | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | — | |
| Short-Term Debt | — | |
| Total Current Liabilities | — | |
| Net Debt | — | |
| Total Debt | — | |
| Total Liabilities | — | |
| EQUITY | ||
| Total Equity | — | |
| Retained Earnings | — | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | — | |
| Shares Outstanding | — | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | — |
| Enterprise Value | — | |
| Enterprise Multiple | — | |
| Enterprise Multiple QoQ | — | |
| Enterprise Multiple YoY | — | |
| Enterprise Multiple IPRWA | — | |
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | — | |
| Asset To Liability | — | |
| Debt To Capital | — | |
| Debt To Assets | — | |
| Debt To Assets QoQ | — | |
| Debt To Assets YoY | — | |
| Debt To Assets IPRWA | — | |
| Debt To Equity | — | |
| Debt To Equity QoQ | — | |
| Debt To Equity YoY | — | |
| Debt To Equity IPRWA | — | |
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | — | |
| Price To Book QoQ | — | |
| Price To Book YoY | — | |
| Price To Book IPRWA | — | |
| Price To Earnings (P/E) | 118.803 | |
| Price To Earnings QoQ | -0.187 % | |
| Price To Earnings YoY | 6.298 % | |
| Price To Earnings IPRWA | high: 246.367 WAT: 118.803 mean: 87.169 median: 78.948 low: -284.104 |
|
| PE/G Ratio | 9.165 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | 83.997 | |
| Forward PE/G | 6.48 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | — | |
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | — | |
| Net Invested Capital | — | |
| Invested Capital | $ 5.1 B | |
| Net Tangible Assets | — | |
| Net Working Capital | — | |
| LIQUIDITY | ||
| Cash Ratio | — | |
| Current Ratio | — | |
| Current Ratio QoQ | — | |
| Current Ratio YoY | — | |
| Current Ratio IPRWA | — | |
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | — | |
| Cost Of Debt | 1.109 % | |
| Interest Coverage Ratio | — | |
| Interest Coverage Ratio QoQ | — | |
| Interest Coverage Ratio YoY | — | |
| Interest Coverage Ratio IPRWA | — | |
| Operating Cash Flow Ratio | — | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | — | |
| Revenue Growth | 0.0 % | |
| Revenue Growth QoQ | -100.0 % | |
| Revenue Growth YoY | -100.0 % | |
| Revenue Growth IPRWA | high: 10.003 % mean: 3.208 % median: 2.058 % WAT: 0.0 % low: -4.928 % |
|
| Earnings Growth | 12.963 % | |
| Earnings Growth QoQ | -132.089 % | |
| Earnings Growth YoY | -58.333 % | |
| Earnings Growth IPRWA | high: 46.602 % WAT: 12.963 % median: 12.5 % mean: 10.855 % low: -57.143 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | — | |
| Free Cash Flow Yield | — | |
| Free Cash Flow Yield QoQ | — | |
| Free Cash Flow Yield YoY | — | |
| Free Cash Flow Yield IPRWA | — | |
| Free Cash Growth | — | |
| Free Cash Growth QoQ | — | |
| Free Cash Growth YoY | — | |
| Free Cash Growth IPRWA | — | |
| Free Cash To Net Income | — | |
| Cash Flow Margin | 0.0 % | |
| Cash Flow To Earnings | 0.0 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | — | |
| Return On Assets QoQ | — | |
| Return On Assets YoY | — | |
| Return On Assets IPRWA | — | |
| Return On Capital Employed (ROCE) | — | |
| Return On Equity (ROE) | — | |
| Return On Equity QoQ | — | |
| Return On Equity YoY | — | |
| Return On Equity IPRWA | — | |
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |